Capecitabine cardiotoxicity - Case reports and literature review

Hepato-Gastroenterology

Volumn 55, Issue 85, 2008, Pages 1249-1256

  Manojlovic, Nebojsa ^a   Babic, Dragana ^b   Stojanovic, Snezana ^c   Filipovic, Ivana ^b   Radoje, Doder ^a  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^c Medical Center Simo Milosevic   (Serbia)

Author keywords

Capecitabine; Cardiotoxicity; Risk factors; Treatment

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; VITAMIN B COMPLEX;

ADENOCARCINOMA; AGED; ANGINA PECTORIS; CASE REPORT; CHEMICALLY INDUCED DISORDER; COLON TUMOR; DOSE RESPONSE; DRUG ADMINISTRATION; HUMAN; MALE; MIDDLE AGED; REVIEW;

ADENOCARCINOMA; AGED; ANGINA PECTORIS; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; VITAMIN B COMPLEX;

EID: 58149398504     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Floyd DJ, Nguyen DT, Raymon IL, Basihr Q, Doll DC, Perry M: Cardiotoxicity of Cancer Therapy. J Clin Oncol 2005; 23(30):7685-7696. (Pubitemid 46291833)
2. Schober C, Papageorgiou E, Harstrick A, Bokemeyer C, Mygge A, Stahl M et al.: Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993; 72:2242-2247. (Pubitemid 23280155)
3. Labianca R, Berreta G, Clerici M, Fraschini P, Luporini G: Cardiac toxicity of 5-fluorouracil: study of 1083 patients. Tumori 1982; 68:505-510. (Pubitemid 13119443)
4. Freeman NJ, Constanza ME: 5-Fluorouracil-associated cardiotoxicity. Cancer 1988; 61:36-45.
5. Jensen AS, Sorensen AB: Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil and capecitabine. Cancer Chemother Pharmacol 2006; 18:1-7.
6. Pai VB, Nahata MC: Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22:263-302. (Pubitemid 30213944)
7. de Forni M, Malet-Martino MC, Jaillais P, et al.: Cardiotoxicity of high -dose continuos infusion of flurouracil: a prospective clinical study. J Clin Oncol 1992; 10:1795-1801. (Pubitemid 23059959)
8. Jeremic B, Jevremovic S, Djuric L, Mijatovic L: Cardiotoxicity chemotherapy treatment with 5-fluorouracil and cisplatin. J Chemother 1990; 2:264-267. (Pubitemid 20322796)
9. Eskilson J, Albertsson M, Merke C: Adverse cardiac effects during induction chemotherapy treatment with cisplatin and 5-fluorouracil. Radiother Oncol 1988; 13:41-46.
10. Meydan N, Kundak I, Yavuzsen T, et al.: Cardiotoxicity of de Gramont's regimen: Incidence, clinical characteristics and long-term foUowup. Jpn J Clin Oncol 2005; 35(2):265-270. (Pubitemid 41444293)
11. Kuppens EIM, Boot H, Beijnen JH, Schellens JHM: Capecitabine induces severe angina-like chest pain. Ann Int Med 2004; 140(6):495.
12. Bertolini A, Flumano M, Fusco O, Muffatti A, Scarinci A, Pontiggia G, Scopelliti M: Acute cardiotoxicity during capecitabine treatment: a case report. Tumori 2001; 87(3):200-206. (Pubitemid 32655970)
13. Saif WM, Quinn MG, Rebecca RT, Ernst A, Grem LJ: Cardiac toxicity associated with capecitabine therapy. Acta Oncologica 2003; 42(4):342-344. (Pubitemid 36851153)
14. Sestito A, Sgueglia GA, Pozzo C, Cassano A, Barone C, Crea F, Lanza GA: Coronary artery spasm induced by capecitabine. J Cardiovasc Med (Hagerstown) 2006; 7(2):136-138. (Pubitemid 44152954)
15. Singer M: Cardiotoxicity and capecitabine: case report. J Clin Nurs 2003; 7(1):72-75.
16. Van Cutsem E, Findlay M, Osterwalder B, et al.: Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18(6):1337-1345. (Pubitemid 30159854)
17. Frickofen N, Beck F-J, Jung B, Fuhr HG, Andrash H, Sigmund M: Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002; 13:797-801. (Pubitemid 34567389)
18. Matthew Ng, Cunningham D, Norman AR: The frequency and cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for addanced colorectal cancer. Eur J Cancer 2005; 41:1542-1546. (Pubitemid 40981835)
19. Cardinale D, Colombo A, Colombo N: Acute coronary syndrome induced by oral capecitabine. Can J Cardiol 2006; 22(3):251-253.
20. Schnetzler B, Popova N, Collao Lamb C, Sappino AP: Coronary spasm induced by capecitabine. Ann Oncol 2001; 12(5):723-724.
21. Rizvi AA, Schauer P, Owlia D, Kalla J: Capecitabine vasospasm-a case report. Angiology 2004; 55(1):93-97.
22. Chau I, Brown G, Cunningham D, et al.: Neoadjuvant capecitabine and eloxatin followed by synchronous chemoradiation and total mesorectal excision in magnet resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006; 24(4):668-674. (Pubitemid 46630432)
23. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R: Italian Trials in Medical Oncology (I.T.M.O.) Group. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100(2):279-287. (Pubitemid 38063635)
24. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19(8):2282-2292. (Pubitemid 32366981)
25. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P: Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19(21):4093-4096.
26. Arbea L, Coma-Canella I, Martinez-Monge R, Garcia-Foncillas J: A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. World J Gastroenterol 2007; 13(14):2135-2137. (Pubitemid 46795857)
27. Wijesinghe N, Thompson PI, McAlister H: Acute coronary syndrome induced by capecitabine therapy. Heart Lung Circ 2006; 15(5):337-339. (Pubitemid 44426248)
28. Becker K, Erckenbrecht JF, Haussinger D, Frieling T: Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999; 57:475-484. (Pubitemid 29196916)
29. Morrow KH, Hoff PM: Does the addition of oxaliplatin increase the risk of capecitabine-induced cardiotoxicity? Nat Clin Pract Oncol 2006; 3(2):76-77.
30. Cvitkovic E, Droz JP, Armand JP, Khoury S (Eds.): Common Toxicity Criteria NCI in Handbook of Chemotherapy in Clinical Oncology. 2nd Edition. Scientific Communication International Ltd, 1993; pp.748-751.
31. Lomeo AM,Avolio C, Iacobellis G, Manzione L: 5-Fluorouracil cardiotoxicity. Eur J Gynaecol Oncol 1990; 11:237-241. (Pubitemid 20295817)
32. Manncuso L: Prinzmetal's angina during 5- fluorouracil chemotherapy. Am J Med 1987; 83:602.
33. Mosseri I, Fingert HJ, Varticovski L, Chokshi S, Isner JM: In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993; 53:3028-3033. (Pubitemid 23210307)
34. Matsubara I, Kamiya J, Imai S: Cardiotoxic effect of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 1980; 30:871-879. (Pubitemid 11162895)
35. Kuzel T, Esparaz B, Green D, Kies M: Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990; 65:885-889. (Pubitemid 20063490)
36. Meyer CC, Calis KA, Burke LB, Walavender CA, Grasela TH: Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997; 17:729-736. (Pubitemid 27318966)
37. Cwikel M, Eskilson J, Albertsson M, Stavenow L: The influence of 5-fluorouracil and methorexate on vascular endothelium. An experimental study using endothelial cells in culture. Ann Oncol 1996; 7:731-737. (Pubitemid 26323547)
38. Oleksowicz L, Bruckner HW: Prophylaxis of 5-fluorouracil induced coronary vasospasm with calcium channel blockers. Am J Med 1988; 85:750-751. (Pubitemid 19015747)
39. Cianci G, Morelli MF, Cannita K, et al.: Prophylastic options in patients with 5-fluorouracil-associated cardiotoxicity. Br J Cancer 2003; 88:1507-1509. (Pubitemid 36713773)
40. Shoemaker LK, Arora U, Rocha Lima CM: 5-Fluorouracil induced coronary vasospasm. Cancer Control 2004; 11(1):46-49.
41. Sudhoff T, Enderle MD, Pahlke M, et al.: 5-Fluorouracil induces arterial vasoconstrictions. Ann Oncol 2004; 15(4):661-664.
42. Klejman NS, Lehane DE, Geyer CE Jr, et al.: Prinzmetal's angina during 5-fluorouracil chemotherapy. Am J Med 1987; 82:566-568.
43. Burger AJ, Mannino S: 5-Fluorouracil induced coronary vasospasm. Am Heart J 1987; 114:433-436.
44. Keefe DL, Roistacher N, Pierri MK: Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 1993; 33(11):1060-1070. (Pubitemid 24002897)
45. Robben NC, Pippas AW, Moore JO: The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 1993; 71:493-509. (Pubitemid 23021241)
46. Budman DR, Meropol NJ, Reugner B, et al.: Preliminary studies of a novel oral fluoropirimidine carbamate: capecitabine. J Clin Oncol 1998; 16:1795-1802.
47. Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B: Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002; 13(3):484-485. (Pubitemid 34705014)